Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,987.00
47,359.00
162,826.00
214,159.00
673,356.00
494,223
Total Accounts Receivable
-
-
3,414.00
3,577.00
-
-
Other Current Assets
461.00
915.00
4,176.00
2,689.00
12,149.00
5,564
Total Current Assets
2,448.00
48,274.00
170,416.00
220,425.00
685,505.00
499,787
Net Property, Plant & Equipment
1,404.00
1,482.00
6,661.00
6,188.00
24,363.00
29,627
Total Investments and Advances
189.00
70.00
1,266.00
55,326.00
4,555.00
-
Other Assets
94.00
99.00
555.00
856.00
1,314.00
10,710
Total Assets
4,135.00
49,925.00
178,898.00
282,795.00
715,737.00
540,124
ST Debt & Current Portion LT Debt
708.00
1,704.00
3,266.00
2,551.00
1,518.00
Accounts Payable
-
-
2,455.00
2,211.00
3,744.00
Other Current Liabilities
2,445.00
5,060.00
12,919.00
23,750.00
37,628.00
Total Current Liabilities
3,153.00
6,764.00
18,640.00
28,512.00
42,890.00
Long-Term Debt
2,274.00
7,703.00
4,072.00
1,518.00
-
Other Liabilities
204.00
29.00
12,207.00
39,687.00
48,877.00
Total Liabilities
5,631.00
14,496.00
34,919.00
69,717.00
91,767.00
Common Equity (Total)
41,454.00
79,382.00
143,979.00
213,078.00
623,970.00
Total Shareholders' Equity
41,454.00
79,382.00
143,979.00
213,078.00
623,970.00
Total Equity
41,454.00
79,382.00
143,979.00
213,078.00
623,970.00
Liabilities & Shareholders' Equity
4,135.00
49,925.00
178,898.00
282,795.00
715,737.00
Non-Equity Reserves
39,958.00
114,811.00
-
-
-

About Blueprint Medicines

View Profile
Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.